Vera Therapeutics reports Q1 EPS ($12.23) vs. ($7.79) last year » 07:2806/2406/24/21
"Over the past nine…
"Over the past nine months, we completed two capital raises for a total of approximately $128M with which we have launched our clinical development program for atacicept," said Marshall Fordyce, MD, founder and CEO. "We recently initiated the Phase 2b ORIGIN trial of atacicept to treat IgAN, which we believe could have a profound benefit for patients for whom there remains significant unmet medical need."
|Over a week ago|
Vera Therapeutics initiated with Buy, $27 target at Jefferies » 07:3306/0806/08/21
Jefferies analyst Maury…
Jefferies analyst Maury Raycroft initiated coverage of Vera Therapeutics with a Buy rating and $27 price target. The company's lead asset atacicept has shown "superior" safety and proof of concept with potential disease-modifying effects, Raycroft tells investors in a research note. Top-line data in IgA nephropathy is expected Q4 of 2022, but stock should move in the second half of 2021 after regulatory feedback, says the analyst.
Vera Therapeutics initiated with an Outperform at Evercore ISI » 06:2506/0806/08/21
Evercore ISI analyst…
Evercore ISI analyst Liisa Bayko initiated coverage of Vera Therapeutics with an Outperform rating and $24 price target, representing 80% upside from current levels. The company is well capitalized to execute the Phase 2 in IgA nephropathy, which could be a $1.5B opportunity, Bayko tells investors in a research note. Vera is also meeting with FDA this year to design what could be a pivotal Phase 2b/3 trial in a second indication for atacicept, lupus nephritis, another underserved market that could be worth $750M, adds the analyst.
Vera Therapeutics initiated with a Buy at Jefferies » 06:1306/0806/08/21
Jefferies analyst Maury…
Jefferies analyst Maury Raycroft initiated coverage of Vera Therapeutics with a Buy rating.
Vera Therapeutics initiated with an Outperform at Cowen » 06:1306/0806/08/21
Cowen analyst Ritu Baral…
Cowen analyst Ritu Baral initiated coverage of Vera Therapeutics with an Outperform rating.
Opening Day: Payment startup dLocal raises $618M in IPO » 08:2306/0506/05/21
CMSL, WKME, PAY, FLYW, DLO, FLGC, GLBE, SMWB, EJH, DBGI, VERA, QNIU, SVFD, RGCB, ELEV, DNUT, AMZN, F, GS, JPM, MS, UBER, LYFT
Payment startup dLocal…
|Over a month ago|
Vera Therapeutics holder Abingworth LLP buys 772K shares of common stock 18:1205/1805/18/21
Opening Day: E-commerce company Global-e valued at $3.6B in debut » 07:3505/1505/15/21
VERA, DBGI, EJH, SMWB, GLBE, IPW, FLGC, DV, PATH, NPCE, RAIN, SWIM, TMCI, SQSP, QNIU, SVFD, RGCB, CMSL, UBER, LYFT, SBUX, HCG, GNW, MS
Global-e Online opened 3%…
Vera Therapeutics opens at $11.41, IPO priced at $11 per share » 10:5005/1405/14/21
Vera Therapeutics (VERA)…
Vera Therapeutics (VERA) priced 4.35M shares at $11.00, below the $14.00-$16.00 range. Jefferies, Cowen and Evercore ISI are acting as joint book running managers for the offering. Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing treatments for patients with serious immunological diseases whose lead program is atacicept, a fusion protein that is in development for IgA nephropathy.
Vera Therapeutics 4.35M share IPO priced at $11.00 » 20:5705/1305/13/21
The deal priced below the…
The deal priced below the $14.00-$16.00 range. Jefferies, Cowen and Evercore ISI are acting as joint book running managers for the offering.